Zydus Cadila and Pieris have entered into an alliance for development and commercialisation of multiple novel Anticalin-based protein therapeutics. The collaboration combines Pieris' drug-discovery and early development capabilities with Zydus' expertise in biologics development, regulatory affairs and biologics manufacturing.
Anticalins are recombinantly engineered versions of human lipocalins. To develop Anticalins, Pieris makes discrete changes to those lipocalin amino acid positions responsible for endogenous ligand binding, thereby redirecting specificity away from the natural ligand and to virtually any target of interest. Anticalin and Anticalins are registered trademarks of Pieris.
Under the terms of the agreement, India-based Zydus will take the lead in advancing Anticalin drug candidates through formal preclinical development and into clinical development, undertaking drug development in accordance with ICH guidelines. Zydus has been granted exclusive marketing rights in India and several other emerging markets, while Germany-based Pieris retains exclusive marketing rights in key developed markets. The most advanced programme in the collaboration is PRS-110, an Anticalin specific for c-Met,a target that is becoming increasingly validated across a broad spectrum of tumours. PRS-110, which is a pure antagonist due to its monovalent target engagement, has demonstrated the ability to inhibit both ligand-dependent and -independent c-Met activity in a variety of animal models.
Through this unique collaborative model, the companies seek to develop candidates to proof-of-concept and will explore out-licencing opportunities in Pieris' territories at the appropriate time. The companies will share licensing revenues on mutually agreed-upon terms.
The Zydus group has been making significant investments in the development and manufacturing of biologics for more than a decade. Zydus has developed a pipeline of 17 biosimilar drugs with six such drugs commercialised and others in clinical development. Zydus has so far advanced two novel biologic drugs to clinical trial stage.
|Agreement Status:||New||Date Announced:||16 Oct 2013|
|Date Last Reported:||Duration:|
|Est Total Value:||Investment To Date:|
|Agreement Type:||Commercialisation Development|
|Generic / Brand Name:||PRS-110|
|Therapeutic Area:||Antineoplastic and Immunomodulating Agents|
|Techonology/Field:||Drug development Therapeutic proteins|